Publications by authors named "L Cerchietti"
Cell motility plays an essential role in many biological processes as cells move and interact within their local microenvironments. Current methods for quantifying cell motility typically involve tracking individual cells over time, but the results are often presented as averaged values across cell populations. While informative, these ensemble approaches have limitations in assessing cellular heterogeneity and identifying generalizable patterns of single-cell behaviors, at baseline and in response to perturbations.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the distinct regions of the germinal center (GC)—the dark zone (DZ) and light zone (LZ)—which are crucial for B-cell expansion and antibody maturation, yet lack a clear understanding of their immune composition differences.
- Researchers discovered specific DNA damage responses and chromatin features that explain why T-cells are excluded from the DZ region, providing insights into its immune-repulsive characteristics.
- The findings highlight the role of the ATR kinase in regulating responses in the DZ, suggesting that targeting ATR could enhance immunotherapy effectiveness for aggressive types of lymphoma like Diffuse Large B-cell Lymphomas (DLBCL).
Cells in the tumor microenvironment (TME) of diffuse large B-cell lymphoma (DLBCL) show enormous diversity and plasticity, with functions that can range from tumor inhibitory to tumor supportive. The patient's age, immune status, and DLBCL treatments are factors that contribute to the shaping of this TME, but evidence suggests that genetic factors, arising principally in lymphoma cells themselves, are among the most important. Here, we review the current understanding of the role of these genetic drivers of DLBCL in establishing and modulating the lymphoma microenvironment.
View Article and Find Full Text PDFUnlabelled: Exportin-1 (XPO1), the main soluble nuclear export receptor in eukaryotic cells, is frequently overexpressed in diffuse large B-cell lymphoma (DLBCL). A selective XPO1 inhibitor, selinexor, received approval as single agent for relapsed or refractory (R/R) DLBCL. Elucidating the mechanisms by which XPO1 overexpression supports cancer cells could facilitate further clinical development of XPO1 inhibitors.
View Article and Find Full Text PDF